Innovent And Lilly’s Rituximab Candidate Accepted By China’s NMPA

 
• By Akriti Seth
  
Lymphoma
Innovent and Lilly expect their rituximab biosimilar to offer an affordable alternative to non-Hodgkin's lymphoma patients • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Regulation

More from Policy & Regulation